ArticleAmerican journal of translational research2025
Combination therapy with otilonium bromide and trimebutine maleate demonstrates significant clinical advantages in irritable bowel syndrome patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Esomeprazole plus trimebutine maleate improves symptoms, esophageal function, and acid control without increasing risks in elderly GERD: a real-world retrospective study.American journal of translational research · 2026Article
- Network pharmacology identifies the mechanisms of action of Jianpi Yanggan Pill in treating diarrhea-predominant irritable bowel syndrome.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of combined otilonium bromide (OB) and trimebutine maleate (TM-906) therapy in patients with irritable bowel syndrome (IBS).
methodsData from 105 IBS patients treated at the Affiliated Hospital of Shaoxing University were retrospectively analyzed. Patients were divided into two groups: the control group (n=50), receiving OB alone, and the observation group (n=55), receiving both OB and TM-906. A comprehensive set of data, including treatment efficacy, safety profiles, clinical symptom improvements, serum markers, and quality of life, were collected from both groups.
resultsThe observation group exhibited significantly higher treatment efficacy and greater improvement in quality of life compared to the control group (P<0.05). The incidence of adverse reactions was similar between groups (7.27% vs. 6.00%, P>0.05). Additionally, the observation group experienced faster symptom relief and a more substantial reduction in inflammatory markers post-treatment (P<0.05).
conclusionsCombined therapy with OB and TM-906 is a safe and effective treatment for IBS, offering quicker symptom relief and substantial improvement in quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.